British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. - sprookjes - yvandenbroek - TriplyDB

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

http://www.wikidata.org/entity/Q43447599

about

Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents Oral fumaric acid esters for psoriasis Oral fumaric acid esters for psoriasis Interventions for nail psoriasis Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis Definition of treatment goals for moderate to severe psoriasis: a European consensus Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective Systemic Treatment of Pediatric Psoriasis: A Review New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review Management of psoriasis patients with hepatitis B or hepatitis C virus infection Psoriasis and comorbid diseases: Implications for management.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Biologic safety in psoriasis: review of long-term safety data.Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.Safety of treatment with biologics for psoriasis in daily practice: 5-year data.Potential role of ustekinumab in the treatment of chronic plaque psoriasis Immunologic biomarkers for clinical and therapeutic management of psoriasis.Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.Biological drugs for the treatment of psoriasis in a public health system.Challenges for synthesising data in a network of registries for systemic psoriasis therapies.Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Management of psoriasis in adolescence.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report.Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial Comparison of microwave ablation, botulinum toxin injection, and liposuction-curettage in the treatment of axillary hyperhidrosis: A systematic review.Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.Biological therapy and dentistry: a review paper.

P2860

Q22305935-31E4BA2E-16DB-4159-9BD6-4DC5ABC5763F Q24187957-21514308-F123-4C1F-A795-A06072207E17 Q24198185-B660F5A0-3F5D-489B-A1C3-53EE276FE4B5 Q24201549-EB341205-3666-48F8-96B1-3672C39C8083 Q24202943-8C3B94FF-2CA0-459C-A272-F5E46F7B22BE Q24234945-E9AAC558-25D2-4E0E-AD0C-9BBDE2BD3618 Q24604445-3DAACEB0-AEA6-4782-9247-573EC0DCC455 Q26747639-16E3357E-CE8F-4F7E-8364-C113203F25C0 Q26753026-ED34D16A-A8EC-4217-ADF0-A92F3D2D8599 Q26800937-545F986B-D0D1-4F04-B435-0B1E99DFB30C Q26829390-B50316F2-DBE1-4DE9-BC33-348BD58AC5EC Q28078157-E4AE5821-1B52-4D1B-9FD5-3D081051773E Q30235888-63B85401-D7AA-45F7-BA4C-467475109CE6 Q30574065-A71C2E96-6232-43EE-B0AF-B495D6B248EE Q30904076-9DF665AD-98B6-4669-8DC1-3939B2451B6D Q33800651-411D4984-5B8C-478A-8D9F-A6D03848E886 Q33841399-F166B63D-075D-42DE-ABCD-696E4608C605 Q33854744-5B0DA427-FD9B-42C0-B21C-652F6F410798 Q33892602-858DA9B0-ABCD-4BB0-BC19-FA6A48CAB030 Q34030644-D34383CA-5A88-489C-A2FD-9B8A089087E9 Q34112840-B20CFB2C-E68C-4F11-944E-D27779581396 Q34142185-4DA6C26B-875B-4BBE-A4C1-F4A22223DF3E Q34190076-D58C02F8-9AE3-4346-A3AE-2BFE0F116346 Q34196035-30F2132B-B3E8-44E6-98C0-2D23FF592095 Q34271894-7E5BA96B-45DE-4A23-A2E5-52A87511552C Q34296816-B86759FB-E307-4415-A35C-7A07BE1DD1B5 Q34356844-B1CB6DD6-4C17-45BB-8748-A79F9E17B05E Q34393068-29BEE5A3-EC16-4664-AE4E-2E7C6823B69D Q34415058-6F993737-EFB6-4058-B008-B14661CC74DD Q34620375-0C639F08-5294-4DE6-B128-966B97E7CD6B Q34944668-AFAF151C-6A5D-4913-84A5-967F4D304986 Q34956195-89D8ED9F-03DF-4706-9826-2A05E35FFD01 Q34996214-E7FD6E1D-1680-47DF-8FD7-7F10A89B18B6 Q35226809-1072F278-616E-4B2B-9AE3-FA88BCE88487 Q35637208-81986031-429C-483C-96B9-8D4AD1C1D5AB Q36174609-37F84320-EDBE-4280-89BC-9E86A0A173CA Q36404862-F4A63048-AA9B-4E32-AF2C-0024C0EFDD5C Q37295966-79805E71-B1E3-44B4-B18F-E3E89095D764 Q37412781-9FD1ED50-9C69-4B87-B59A-832585AD099F Q37550670-C05F9A50-A12D-4190-B553-C47DA9088B7D

P2860

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

http://www.wikidata.org/entity/Q43447599

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

British Association of Dermato ...... erventions for psoriasis 2009.

@en

British Association of Dermato ...... erventions for psoriasis 2009.

@nl

type

label

British Association of Dermato ...... erventions for psoriasis 2009.

@en

British Association of Dermato ...... erventions for psoriasis 2009.

@nl

prefLabel

British Association of Dermato ...... erventions for psoriasis 2009.

@en

British Association of Dermato ...... erventions for psoriasis 2009.

@nl

P1433

Q43447599-4F5079D8-B209-43CF-B8C6-AAEC1C6C724A

P1476

Q43447599-5AEBCA86-A97D-4C4A-8DE0-7B7EEA8342CE

P2093

Q43447599-0035171B-C602-45B3-BCD0-D832B5167CCF

Q43447599-3184EF77-53A2-4FA0-8F47-35F3CC8B99EC

Q43447599-38C13F05-3A52-44F7-A34B-CA76282B42AD

Q43447599-47746CEF-B1C5-4730-99C7-AB339D6404EB

Q43447599-87D54520-958F-4885-8EB8-2A0BE511799E

Q43447599-C57EFC8D-6EFF-4042-B009-D007EDBD3C85

Q43447599-CBA2C275-F0A1-4F69-8CF0-23AABD39BC26

Q43447599-D5374222-BAC7-48E0-AE49-448616CD260F

Q43447599-F1F471F1-D0FE-4B88-8984-6F494F6946C7

Q43447599-FEDF2119-0831-484A-A6B0-55E69219FD51

P2860

Q43447599-36842A72-D3D5-4133-9313-A45988081422

Q43447599-C65CEE55-896E-4F2C-8116-C1DE2CF85FD1

P304

Q43447599-C574C03E-D360-4880-93F8-E3BB41861B7A

P31

Q43447599-37334F58-698B-4E8D-A06E-5022712C7339

P356

Q43447599-FEE0782A-C2A7-4012-BC12-C640EB36BAC0

P407

Q43447599-AA795D31-2B72-4819-9D3D-39B55343C0E3

P433

Q43447599-0E2BEA23-4947-4785-9A25-DB86DEF4F7C9

P478

Q43447599-7DD888CA-EE8C-4FFE-A403-DB58C32720FB

P50

Q43447599-26976A01-349C-455C-A944-0D4303BBA6E2

Q43447599-AA1D2EEE-D84C-40C3-B32C-60D63481FB80

Q43447599-B3BBEF3F-2A07-42E8-BB13-95F16D8A86B1

Q43447599-D01C1930-B425-49F2-A644-CD8121ED1C5D

P577

Q43447599-99C62411-ED82-431F-B80C-612DF7EE3BA9

P5875

Q43447599-AFDA1322-139A-4096-9D56-080698E84BCD

P698

Q43447599-62EA924B-F86F-41C1-B53C-57CE02F5D96C

P356

J.1365-2133.2009.09505.X

P1433

British Journal of Dermatology

P1476

British Association of Dermato ...... terventions for psoriasis 2009

@en

P2093

(Chair of Guideline Group)

http://www.w3.org/2001/XMLSchema#string

A D Burden

http://www.w3.org/2001/XMLSchema#string

A D Ormerod

http://www.w3.org/2001/XMLSchema#string

A V Anstey

http://www.w3.org/2001/XMLSchema#string

C H Smith

http://www.w3.org/2001/XMLSchema#string

D A Chandler

http://www.w3.org/2001/XMLSchema#string

K E McKenna

http://www.w3.org/2001/XMLSchema#string

K Jackson

http://www.w3.org/2001/XMLSchema#string

N J McHugh

http://www.w3.org/2001/XMLSchema#string

R J G Chalmers

http://www.w3.org/2001/XMLSchema#string

P2860

Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

The effect of tumor necrosis factor on human sperm motility in vitro.

P304

987-1019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2133.2009.09505.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Y. Finlay

Christopher Griffiths

Jonathan N. Barker

Nick J Reynolds

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38036576

http://www.w3.org/2001/XMLSchema#string

P698

19857207

http://www.w3.org/2001/XMLSchema#string